Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prime Medicine, Inc. - Common Stock (NQ:PRME)

3.410 -0.180 (-5.01%)
Streaming Delayed Price Updated: 3:50 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prime Medicine, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Pricing of Upsized Public Offering
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Proposed Public Offering of Common Stock
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
2 gene editing stocks to keep on your 2024 watchlist
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
Via MarketBeat
News headline image
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Investor Conferences in June
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Virtual Investor Conferences in May
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
From Prime Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.